Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 14/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27552233 | 1.00 | TSHR (0.40) | TSHRTRPV3CYP2D6CYP2C19TDP1 | |
| SCHEMBL24177276 | 0.82 | TSHR (0.38) | TSHRTRPV3CYP2D6CYP2C19TDP1 | |
| SCHEMBL9949236 | 0.78 | LMNA (0.42) | TSHRTRPV3TDP1 | |
| SCHEMBL15896620 | 0.78 | — | — | |
| SCHEMBL10282636 | 0.76 | — | — | |
| SCHEMBL3966902 | 0.76 | KMT2A (0.33) | — | |
| SCHEMBL10282653 | 0.76 | — | — | |
| SCHEMBL13743167 | 0.76 | — | — | |
| SCHEMBL13519644 | 0.75 | TSHR (0.36) | TSHRTRPV3TDP1 | |
| Hydrochloric Acid SCHEMBL6123301 | 0.74 | KMT2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | TSHR 67/4885TRPV3 795/4885CYP2D6 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.